Pradaxa^® (150mg and 110mg hard capsules) is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular AF, with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension.^1,2

Praxbind^® is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa^® (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: • For emergency surgery/urgent procedures • In life-threatening or uncontrolled bleeding.³

For more information, or to access the current prescriber guide and summary of product characteristics, please visit www.medicines.org.uk/emc (UK) or www.medicines.ie (Ireland).

Adverse events should be reported. 
UK: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) or by email to PV_local_uk_ireland@boehringer-ingelheim.com.
IE: Reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 291 3960 or by email to PV_local_uk_ireland@boehringer-ingelheim.com.